The FDA today issued a Public Health Advisory regarding Trasylol (aprotinin, made by Bayer), warning doctors who prescribe this medication to closely monitor patients’ toxicity levels.
The drug, which is prescribed after bypass surgery to prevent blood loss, has been found in studies by the New England Journal of Medicine and Transfusion to lead to “higher risks of kidney problems, heart attacks, and strokes” in patients undergoing the procedure.
